Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
5.59
+0.16 (2.95%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Cytek Biosciences Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 206.71 | 201.49 | 200.45 | 193.02 | 164.04 | 127.95 |
Revenue Growth | 5.45% | 0.52% | 3.85% | 17.67% | 28.20% | 37.82% |
Gross Profit Gross Profit Growth | 107.23 | 104.46 | 111.11 | 109.43 | 100.97 | 79.14 |
Operating Income Operating Income Growth | -47.45 | -40.38 | -20.52 | -27.85 | -1.8 | 9.16 |
Net Income Net Income Growth | -80.58 | -66.54 | -6.02 | -12.15 | 2.58 | 0.05 |
Earnings Per Share EPS Growth | -0.63 | -0.52 | -0.05 | -0.09 | 0.02 | 0.00 |
EPS Growth | - | - | - | - | 2906.28% | -99.36% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
United States United States Growth | 105.43 | 95.25 | 92.61 | 102.09 | 94.59 | 72.72 |
EMEA EMEA Growth | 54.08 | 55.88 | 62.34 | 53.18 | 43.96 | 36.97 |
APAC APAC Growth | 39.99 | 41.08 | 35.77 | 31.6 | 22.52 | 16.08 |
Other Other Growth | 7.22 | 9.28 | 9.73 | 6.15 | 2.96 | 2.18 |
Total Total Growth | 206.71 | 201.49 | 200.45 | 193.02 | 164.04 | 127.95 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 262 | 261.53 | 277.86 | 262.41 | 341.15 | 364.62 |
Total Debt Total Debt Growth | 26.46 | 23.74 | 17.02 | 14.14 | 18.09 | - |
Net Cash (Debt) Net Cash Growth | 235.54 | 237.79 | 260.85 | 248.27 | 323.06 | 364.62 |
Net Cash Growth | -1.17% | -8.84% | 5.06% | -23.15% | -11.40% | 124.44% |
Net Cash Per Share Net Cash Per Share Growth | 1.83 | 1.86 | 2.00 | 1.84 | 2.33 | 4.47 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -6.04 | -4.69 | 25.38 | 5.28 | -12.23 | 4.63 |
Capital Expenditures CapEx Growth | -6.04 | -4.08 | -3.53 | -4.65 | -9.75 | -4.36 |
Free Cash Flow Free Cash Flow Growth | -12.08 | -8.77 | 21.85 | 0.63 | -21.98 | 0.27 |
Free Cash Flow Growth | - | - | 3352.45% | - | - | -98.05% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 51.88% | 51.84% | 55.43% | 56.69% | 61.56% | 61.86% |
Operating Margin | -22.95% | -20.04% | -10.24% | -14.43% | -1.10% | 7.16% |
Pretax Margin | -19.75% | -14.81% | -2.84% | -8.14% | 0.77% | 4.64% |
Profit Margin | -38.98% | -33.02% | -3.00% | -6.29% | 1.57% | 0.04% |
FCF Margin | -5.84% | -4.35% | 10.90% | 0.33% | -13.40% | 0.21% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 534.49 | 41969.36 |
Forward PE | - | 89.56 | 26.14 | 245.06 | 44.39 | 152.95 |
P/FCF Ratio | - | - | 38.25 | 1952.94 | - | 8204.54 |
PS Ratio | 3.52 | 3.21 | 4.17 | 6.41 | 8.39 | 17.06 |